BL-8020 acts via a unique mechanism of action, by inhibiting hepatitis C virus-induced autophagy (cell degredation), which differs from the mechanism of currently used anti- hepatitis agents
sounds to me like it modifies host factors like the debiopharma compound NVS licensed
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.